-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q1 Revenue $13.6M
4:27PM ET 5/12/2022 MT Newswires...
...
Alpine Immune Sciences (ALPN) on Thursday widened its net loss to $0.52 per share in Q4 from $0.27 per share a year earlier. Analysts polled by Capital IQ...
...
Alpine Immune Sciences (ALPN) said Monday the US Food and Drug Administration placed its clinical study of davoceticept in combination with pembrolizumab...
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%,...
Address | 188 East Blaine Street Seattle, Washington 98102 |
Phone | +1.206.788.4545 |
Number of Employees | 48 |
Recent SEC Filing | 05/12/2022![]() |
Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
President & Head-Research & Development | Stanford L. Peng |
Finance Director | Thaedra Thullberry |
Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
Price Open | $6.72 |
Previous Close | $6.71 |
52 Week Range | $6.00 - 15.14 |
Market Capitalization | $229.0 M |
Shares Outstanding | 30.3 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 08/09/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$1.97 |
Beta vs. S&P 500 | N/A |
Revenue | $705.0 K |
Net Profit Margin | -214.70% |
Return on Equity | -59.07% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |